RxDoctor Payments Data

Irfan Ahmed, MD

Radiation Oncology · Palm Coast, FLNPI 1548222490

Payments from drug & device makers

$7,347in general payments, 2019–2025

Across 284 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$2K
  • AstraZeneca$577
  • Johnson & Johnson$449
  • Incyte Corporation$401
  • Seagen Inc.$394
  • Novartis$372
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$7,347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exelixis Inc.1$1,559
AstraZeneca(2 entities)32$577
Johnson & Johnson23$449
Incyte Corporation21$401
Seagen Inc.20$394
Novartis21$372
Amgen15$278
Sobi, Inc2$207
Foundation Medicine, Inc.6$194
Merck9$185
Daiichi Sankyo Inc.9$167
Eisai Inc.8$151
Bayer8$142
Lilly USA, LLC7$132
Sanofi6$125
Jazz Pharmaceuticals Inc.6$119
Regeneron Healthcare Solutions, Inc.5$116
E.r. Squibb & Sons, L.L.C.1$114
Pharmacyclics LLC, An Abbvie Company5$106
Roche Diagnostics Corporation1$100
Pfizer7$100
Ipsen Biopharmaceuticals, Inc5$88
Servier Pharmaceuticals LLC5$83
Takeda Pharmaceuticals U.S.A., Inc.4$81
Morphosys, US Inc.4$76
Puma Biotechnology, Inc.3$58
Tersera Therapeutics LLC2$55
Genentech USA, Inc.3$51
Pharmacosmos Therapeutics Inc.2$50
Array Biopharma Inc3$49
Beigene USA, Inc.3$45
Gilead2$44
Adaptive Biotechnologies Corporation2$43
EMD Serono, Inc.2$42
Mirati Therapeutics, Inc.2$40
Boehringer Ingelheim2$37
G1 Therapeutics, Inc.2$35
Genmab U.S., Inc.1$34
Teleflex LLC1$28
Immunogen, Inc.1$28
Spectrum Pharmaceuticals Inc.1$28
Karyopharm Therapeutics Inc.2$27
Aurobindo Pharma USA, Inc.1$24
Tolmar, Inc.1$23
Blue Earth Diagnostics1$22
Apellis Pharmaceuticals, Inc.1$22
Blueprint Medicines Corporation1$20
Stemline Therapeutics Inc.1$19
Tolmar Pharmaceuticals, Inc.1$19
Bristol Myers Squibb1$19
Boston Scientific1$17
Sun Pharmaceutical Industries Inc.1$17
Syndax Pharmaceuticals, Inc.1$17
Recordati_rare_diseases_inc.1$17
Rigel Pharmaceuticals, Inc.1$16
GSK1$16
Kyowa Kirin, Inc.1$14
Myovant Sciences Inc.1$14
Myriad Genetic Laboratories, Inc.1$13
Novocure Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,347 in reported general payments places this provider in the 80th percentile of 465 radiation oncology providers in Florida.

See all radiation oncology providers in Florida

Medicare billing

Part B allowed, 2024
$473,989
Medicare patients
286
Services billed
6,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl12$122

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →